Botulinum Toxin A for Chronic Pelvic Pain
Author Information
Author(s): Melle A. Spruijt, Wenche M. Klerkx, Kim Notten, Hugo van Eijndhoven, Leonie Speksnijder, Manon H. Kerkhof, Kirsten B. Kluivers
Primary Institution: Radboud University Medical Center
Hypothesis
Women with chronic pelvic pain receiving BTA injections in combination with PFMT will experience greater reductions in pain and improvements in quality of life compared to those receiving placebo injections with PFMT.
Conclusion
The results from this study do not support the use of BTA injections in the management of chronic pelvic pain in women.
Supporting Evidence
- 33% of participants in the BTA group reported a 33% reduction in pain compared to 20% in the placebo group.
- Pelvic floor resting activity decreased significantly after BTA treatment compared to placebo.
- Both groups showed similar changes in average pain scores over the 26-week follow-up.
Takeaway
This study looked at whether a special injection could help women with pelvic pain feel better. It found that the injection didn't really help more than a fake one.
Methodology
Participants received either BTA injections or placebo injections into the pelvic floor muscle, followed by four PFMT sessions.
Potential Biases
Envelope randomisation may introduce bias, although baseline characteristics were similar between groups.
Limitations
The study was affected by the COVID-19 pandemic, which led to cancellations of follow-up visits and potential biases in the results.
Participant Demographics
The study included 94 women with chronic pelvic pain, median age 47 years, predominantly Caucasian.
Statistical Information
P-Value
0.19
Confidence Interval
95% CI 0.72–4.90
Statistical Significance
p=0.19
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website